Nan Fung
Life Sciences

Focused on innovation and growth in Life Sciences


A global Investor in Life Sciences

Our deep resources, commitment, and knowledge within the Nan Fung Life Sciences family of investment companies make us the ideal partners to scientists, entrepreneurs, and corporations around the world. With a diverse set of experiences, skills, and a track record in company formation, venture capital, and scientific innovation, we focus on delivering opportunities to investors who seek to benefit from long-term value.

Nan Fung Life Sciences

Global Life Sciences Investment Platform

Pivotal Life Sciences >

Global Life Sciences Asset Management Platform

Pivotal bioVenture Partners (US)

Global Life Sciences VC Investor
(excluding Asia)

Pivotal bioVenture Partners (China)

Life Sciences VC Investor
Based in China

Public Investment >

Life Sciences Public

NFLS Platform
Companies >

Building Life Sciences Companies

Fund & Co
Investments >

Investing in Life Sciences Funds


We have an important job to do. Find your role.


Arcutis Announces Positive Topline Results from ARRECTOR Pivotal Phase 3 Trial of Roflumilast Foam 0.3% in Scalp and Body Psoriasis

Study met both co-primary endpoints and all secondary endpoints. At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle
At week eight, 46.5% of individuals treated with roflumilast foam achieved Body-Investigator Global Assessment (B-IGA) Success compared to 20.8% of individuals treated with vehicle
Once-daily roflumilast foam demonstrated a favorable safety and tolerability profile

Rallybio Announces Positive Preliminary Results for RLYB212, an anti-HPA-1a Monoclonal Antibody for the Prevention of Fetal and Neonatal Alloimmune Thrombocytopenia

NEW HAVEN, Conn.–(BUSINESS WIRE)–Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary results from its ongoing Phase 1b proof-of-concept study of RLYB212, an anti-HPA-1a monoclonal antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). These data demonstrate that one week after a single subcutaneous dose, RLYB212 was able to eliminate transfused HPA-1a positive platelets rapidly compared to placebo in a challenge model of a catastrophic fetal maternal hemorrhage. Additional pharmacokinetic data suggests the opportunity for less frequent dosing.

Evommune Initiates Phase 2a Proof-of-Concept Clinical Trial to Evaluate EVO101 in Atopic Dermatitis

Palo Alto, Calif., Sept. 28, 2022 – Evommune, Inc., a clinical-stage biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced enrollment of the first patient in a Phase 2a proof-of-concept clinical trial evaluating EVO101, a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), in patients with atopic dermatitis (AD). The Phase 2a trial is a randomized, double-blind, parallel group, vehicle-controlled study which will assess the safety, tolerability and preliminary efficacy of EVO101 topical cream, 0.1% BID, in 118 adults with mild to moderate AD in clinical sites
across the United States.

Plexium Strengthens Leadership Team With Appointment of Daniel Sipes As Senior Vice President, Head of Technology

Plexium, Inc. (Plexium), a leading next-generation targeted protein degradation (TPD) company, today announced the appointment of Daniel Sipes as Senior Vice President, Head of Technology. Mr. Sipes brings over two decades of experience in developing and implementing new technologies for drug discovery to Plexium, with a focus on next-generation high throughput screening and novel assay development.